Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. by Aydogan, M et al.
Respiratory Medicine (2013) 107, 1322e1329Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedSublingual immunotherapy in children with
allergic rhinoconjunctivitis mono-sensitized
to house-dust-mites: A double-blind-
placebo-controlled randomised trial*Metin Aydogan a,1, Aarif O. Eifan a,b,*,1, Sevgi Keles a,
Tunc Akkoc a, Mustafa A. Nursoy a, Nerrin N. Bahceciler a,c,
Isil B. Barlan aa Pediatric Allergy and Immunology, Marmara University Medical Faculty, Istanbul, Turkey
bAllergy and Clinical Immunology, NHLI, Imperial College, London, UK
c Pediatric Allergy and Immunology, Near East University, Faculty of Medicine, North Nicosia, CyprusReceived 4 April 2013; accepted 26 June 2013
Available online 23 July 2013KEYWORDS
Allergy;
Asthma;
Conjunctivitis;
Dust mite;
Rhinitis;
Sublingual
immunotherapyAbbreviations: AIT, Allergen immunot
inae; HDM, House-dust-mite; ICS, In
allergen-HDM nasal provocation; SCIT,
* Part of the data of this study were
immunotherapy for treating allergic c
* Corresponding author. Allergy and
E-mail addresses:mmetinaydogan@
tuncakkoc@marmara.edu.tr (T. Akkoc
1 These authors contributed equally
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Background: Although sublingual immunotherapy (SLIT) has been demonstrated to be a safe
and efficient treatment in children with seasonal allergic rhinitis (AR), there is little evidence
on the efficacy of SLIT with house-dust-mite (HDM) extract in children with isolated perennial
AR.
Objectives: We sought to assess the clinical efficacy and safety of HDM-SLIT in children with
isolated allergic rhinitis-conjunctivitis mono-sensitized to HDM without asthma symptoms.
Methods: Twenty-two children (aged 5e10 years) with perennial AR and conjunctivitis symp-
toms mono-sensitized to Dermatophagoides pteronyssinus and Dermatophagoides farinae were
enrolled. During a 2 months run-in period, symptom and medication scores, lung functions,
bronchial hyperreactivity, nasal provocation and skin prick tests were evaluated.herapy; AR, Allergic rhinitis; Der P, Dermatophagoides pteronyssinus; Der f, Dermatophagoides far-
haled corticosteroids; mBHR, Methacholine-non-specific bronchial hyperreactivity; sNPT, Specific
Subcutaneous immunotherapy; SLIT, Sublingual immunotherapy.
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HDM-SLIT in rhino-conjunctivitis children 1323Subjects were randomized to active or placebo using a double-blind method. A total of eigh-
teen subjects were randomised to receive either active SLIT or placebo for 12 months. Daily
symptom and medication scores, baseline lung functions, bronchial hyperreactivity, nasal
provocation and skin prick tests were recorded and re-evaluated at the end of treatment.
Results: After one year of treatment, no significant differences were detected in the between
groups and within group comparisons based on total rhinitis symptom/medication scores
(p > 0.05). Skin reactivity to Dermatophagoides pteronyssinus was significantly reduced in
HDM-SLIT compared to placebo group (p Z 0.018). A significant reduction in nasal sensitivity
was observed in SLIT group after one year treatment when compared to baseline
(pZ 0.04). Total conjunctivitis symptoms were reduced significantly in both active and lacebo
group at the end of treatment compared to baseline. The proportion of patients with non-
specific bronchial hyperreactivity increased to almost 3-fold in placebo group compared to
baseline.
Conclusion: HDM-SLIT was not superior to placebo in reducing isolated rhinoconjunctivitis
symptoms within 12 months of treatment. However, HDM-SLIT has a modulating effect on
allergen-specific nasal and skin reactivity in isolated perennial AR children.
Clinical Trial Registration: The trial was registered at Anzctr.org.au number, ACTRN1261
3000315718.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The prevalence of atopic diseases such as allergic rhinitis
has increased in the past three decades in children and
adults [1]. House-dust-mites (HDM) are common allergens
worldwide and their major allergens Dermatophagoides
pteronyssinus and Dermatophagoides farinae mites coexist
in most geographical regions. Approximately 85% who have
respiratory allergies are typically HDM-allergic [2]. Use of
environmental control has been found to be of no effect in
reducing asthma/rhinitis symptoms [3,4]. Treating with
rescue medications and corticosteroids might control
symptoms of allergic rhinitis but does not modify the nat-
ural course of the disease.
Allergen immunotherapy (AIT) is the treatment modality
that might modify the course of allergic disease by pre-
venting its exacerbation, reducing the risk of new allergic
sensitizations and preventing the development of clinical
asthma in children treated for seasonal allergic rhinitis
(AR) [5].
Considerable amount of sublingual immunotherapy
(SLIT) trials done in pollen induced AR showed successful
treatment and long term effect of SLIT in suppressing AR
symptoms and reduction of medication in children [6e8],
while majority of HDM-SLIT trials in children and adults
included more asthmatics patients, showing wide hetero-
geneity and has been shown to be more effective in
asthmatics [9]. Few randomised control trials have evalu-
ated efficacy of SLIT on specific individual components of
airway disease such as conjunctivitis or rhinitis, rather
global effect on allergic airways [10]. Studies evaluating
the efficacy of SLIT in children with isolated perennial
rhinitis and or conjunctivitis monosensitised to HDM are
needed.
The aim of the present study was to evaluate the clinical
efficacy of HDM-SLIT in children with isolated allergic
rhinitis and/ conjunctivitis without asthma symptomsmonosensitised to HDM by a prospective randomized,
double-blind-placebo-controlled trial.Methods
Study design
Children under 10 years of age suffering from persistent
allergic rhinitis according to Aria [11] without asthma,
caused by D. pteronyssinus and D. farinae (monosensitised)
confirmed by skin prick and specific IgE were enrolled from
allergy clinic. All eligible patients underwent an eight-week
run-in period to evaluate their baseline clinical conditions
by means of symptom/medication scores, lung functions,
methacholine-non-specific bronchial hyperreactivity
(mBHR), specific allergen-HDM nasal provocation (sNPT)
and skin prick tests reactivity (SPT). Computer-generated
randomization at the site of production of the medication
was used for allocation of subjects to either active or pla-
cebo group in a double-blind manner. Randomization codes
were kept securely to be accessed after the end of
treatment.
Regular visits for clinical evaluation (symptom and
medication score), safety assessment and spirometric pul-
monary function tests were scheduled for every 3 months.
At the end of one year, mBHR, NPT and SPT were re-
evaluated.
The primary outcomes were symptom and medication
scores for rhinitis and conjunctivitis. Secondary parameters
were the assessment of SPT reactivity, new sensitizations,
mBHR and specific-NPT. This study was conducted in
accordance with the amended Declaration of Helsinki. The
study protocol was approved by the Ethics Committee of the
Medical Faculty of Marmara University with the approval
number MAR-YC-2004-0147 and written consents were taken
from all parents of children. The trial was registered at
1324 M. Aydogan et al.Anzctr.org.au number, ACTRN12613000315718. The study
design is summarized in Fig. 1.
Patients
Children aged between 5 and 10 years of both genders with
the history of persistent HDM-induced allergic rhinitis ac-
cording to ARIA guidelines [11] without asthmatic symptoms
were enrolled. Diagnosis of childhood asthma was made ac-
cording to theGlobal Initiative for Asthma guidelines [12]. All
patients had to have skin test positivity only to HDM (D.
farinae or D. pteronyssinus or both). Patients with asthma
symptoms, polysensitization to other aeroallergens, nega-
tive sNPT to Der f1 and Der p1, which are the major allergen
extracts of D. farinae and D. pteronyssinus, respectively,
systemic immunologic disorders, previous use of allergen
immunotherapy or using oral/inhaled corticosteroids for any
reason were excluded from the trial. All patients were
instructed to take avoidancemeasures against HDM including
use of impermeable mattress and pillow covers.
Treatment
After an 8-week run-in period, patients were randomly
selected to receive either active SLIT or placebo. The
standardized extract used throughout the study had the
same batch of equal proportions of 50%:50% mixture of D.
pteronyssinus and D. farinae (STALORAL, Stallergenes SA,
Antony, France). The allergen extracts were graded into
two concentrations: 10 and 300 IR/ml. The Der p1 and Der
f1 contents of 1 ml of 100 IR allergen extract used in this
study were 26.3 and 63.4 mg, respectively.
During the first 6 days, the patients took daily increasing
doses in the form of 1e10 drops of the 10 IR/mL extract. For
reaching maintenance dose, 300 IR/mL concentration vials
were initiated on the 7th day starting from 1 and reaching toFigure 1 Randomized double-blind-placebo control CONSORT flo
immunotherapy; PFT, pulmonary function test; SPT, skin prick te
provocative test.8 drops on the 11th day. Following this, all patients took 8
drops sublingually 3 times a week for 12 months. Patients on
placebo took their drops in the same manner. Drops were
held under the tongue for two minutes and then swallowed,
according to the manufacturer’s instruction. The cumulative
dose was approximately 44500 IR, which was equivalent to
11.7 mg of Der p1 and 28.2 mg of Der f1.
Symptoms and medication scores
Patientswith/or their parentswere instructed to keep a diary
during the treatment period, for daily evaluation of symp-
toms according to a 4-point scoring system: 0 (no symptoms)
to 3 (severe symptoms) for each rhinitis and conjunctivitis
symptoms (sneezing, nasal discharge, itching and nasal
obstruction; itchy, red and watery eyes). Asthma symptoms
were recorded as wheezing, breathlessness, dyspnoea and
cough. When necessary, patients were allowed to use anti-
histamines and/or intranasal corticosteroids. Other medica-
tions, such as long-lasting antihistamines, inhaled
corticosteroid, and oral corticosteroids, were not permitted
during the study. Thepatients had to recordon the samediary
card whenever they used medications (1 point: one puff of
intranasal steroids per nostril, 2 points: one dose of antihis-
tamine). The individual daily symptomandmedication scores
were recorded on a daily basis for the entire period of the
study and themonthlymean scoreswere recorded at every 3-
monthly study visit. Adverse reactions were classified ac-
cording to the European Academy of Allergy and Clinical
Immunology (EAACI) grading system [13].
Skin prick testing
Skin prick tests were performed with 20 common aero-
allergens belonging to five groups; mites (D. farinae, D.
pteronyssinus), molds (Alternaria, Aspergillus mix,w diagram of participants through each stage. SLIT, sublingual
st; sNPT, specific nasal provocation test; Mch, methacholine
HDM-SLIT in rhino-conjunctivitis children 1325Penicillium mix, Candida albicans), pollens (Betulaceeae,
Aesculus Hippo, Olea Europea, Plantago, Artemisia, Pari-
etaria, Secale cereale, Triticum vulgaris, Zea mays,
mixture of 5 grasses), animal dander (feathers mixture, cat
hair, dog hair) and insects (cockroach) (Stallergenes, Ant-
ony, France). Histamine and saline were used as positive
and negative controls, respectively. A drop of each allergen
extract was placed on the volar surface of the left forearm
and was penetrated with a separate lancet. After 15 min,
the wheal reaction was measured as the mean of the
longest diameter and the diameter perpendicular to it. A
wheal diameter of at least 3 mm greater than those of the
negative controls was considered as positive.
Nasal provocation test
The nasal provocation test was performed with Der p1 and
Der f1 50/50 allergen extract (Stallergenes, Antony, France)
using increasing concentrations of 0.1, 1, 10 and 100 IR/ml at
the dosage of one puff (100 ml) into each nostril. A score was
established (0: absent, 1: mild 2: moderate, 3: severe) for
each of the rhinitis symptoms (sneezing, rhinorrhea, blocked
nose and itching). If a total score of at least 8 was not
reached with the lowest concentration after 10 min of
application, the following doses were sequentially used.
Nose clips were immediately applied after application of
allergen and children were asked to breathe through their
mouth for atleast 1min to prevent the allergen being inhaled
and ensure applied allergen is locally. The test was per-
formed at the beginning and end of the treatment.
PFT and methacholine challenge
Lung functions were assessed with a spirometer (Sensor-
medics, S3513, California, USA). To induce bronchial provo-
cation, the nebulizer was attached to a dosimeter (Mediprom
FDC 88, France) that consisted of a breath-activated solenoid
valve and a source of compressed air (pressure, 20 psi). The
solenoid valve was set to remain open for 0.4 s when trig-
gered by the subject’s inspiratory effort. Methacholine
challenge test was performed using American Thoracic So-
ciety (ATS) guidelines [14]. Briefly, the baseline FEV1 was
measured, the subjects inhaled five breaths of saline solution
diluents and the measurements were repeated after a 2-min
interval. Subjects inhaled the aerosolized solutions in five
breaths from end-tidal volume to full inspiratory capacity via
a mouth-piece. Starting from 0.031 mg/mL concentration,
the subsequent methacholine dilutions were increased in a
doubling manner until the provocative concentration of an
inhaled agonist producing a 20% decrease in FEV1 (PC20) is
achieved compared to the value recorded at baseline. At the
end of each experiment, the subjects were given two in-
halations of albuterol to reverse any residual bronchocon-
striction. A PC20 value less than 8 mg/mL was considered as
positive for bronchial hyperresponsiveness.
Statistical analysis
Qualitative data were analyzed by the chi-square test or
Fisher’s exact test. Symptoms, medication intake, skin
tests, lung functions, nonspecific bronchial hyperreactivity(BHR), and nasal provocation test were analyzed statisti-
cally by nonparametric tests; the Wilcoxon rank sum test
was used for intragroup analysis, and the ManneWhitney
U-test for intergroup analysis. All tests were two-tailed,
and the level of significance was set at p < 0.05. Statisti-
cal analyses were performed using the Statistical Package
for the Social Sciences, SPSS 13.0 (SPSS Inc., Chicago, IL,
USA).Results
Participants
Twenty-two children (mean  SD age 7.5  2.1 years;
range: 5e10 years) suffering from allergic rhinitis without
asthma caused by HDM were recruited into the study. Four
patients dropped-out during run-in period; of which two
developed asthma symptoms, one refused to continue
participation and 1 had a negative nasal provocation
testing. Overall, 18 patients were included for randomiza-
tion and all were allocated for interventions (Fig. 1).
During the up-dosing period of the treatment, two patients
dropped out, one due to side effects and the other lost of
follow-up finalizing the study with 16 subjects who had
provided at least one primary outcome. The mean duration
of rhinitis symptoms was 21.5  16.4 months. All patients
had rhinitis symptoms while 3 in active and 6 in placebo
group had concomitant conjunctivitis symptoms. The
baseline clinical and demographic characteristics of the
subjects in both groups were homogeneous (Table 1).Symptom and medication scores
There were no statistical difference for all four rhinitis in-
dividual symptoms scores (sneezing, nasal itching, nasal
blockage, and rhinorhea) between active and placebo and
within the groups (p > 0.05). Total rhinitis symptom and
medication scores were not significantly different between
active and placebo and within the groups during the whole
duration of treatment (Table 2, Fig. 2A).
A significant reduction of total conjunctivitis symptoms
were observed in both groups at the end treatment when
compared to baseline, but no difference with regard to
either individual conjunctivitis symptoms or total conjunc-
tivitis symptoms were observed between active and placebo
at the end of treatment (p > 0.05, Fig. 2B). No significant
differences were reported for non-rhinoconjuctivitis symp-
toms such as cough, wheezing or other asthma symptoms.Skin reactivity
Evaluation of skin reactivity revealed a significant decrease
of Dermatophagoides pteronyssinus wheal size after one
year of treatment in active group when compared to pla-
cebo (pZ 0.018), whereas there was no significant change
observed in Dermatophagoides farinae wheal size in be-
tween and within the groups (p > 0.05, Fig. 3). There were
no new sensitizations observed after one year of SLIT.
Table 1 Demographics and clinical characteristics of patients at screening.
Patient (n) Treatment
Active Placebo p Value
Number of subjects 16 7 9
Sex (m/f) 12/4 6/1 6/3 >0.5
Mean age (years [SD]) 8.1  2.2 7.3  2.3 >0.5
Mean duration of rhinitis (month [SD]) 22.3  17.9 20.3  17.2 >0.5
Total rhintis symptoms score (mean  SD) 3.6  3.8 2  1.6 >0.5
Total medication score (mean  SD) 0.5  0.5 0.3  0.3 >0.5
D.fa mean wheal (mm[SD]) 6.4  2.5 3.9  1.8 >0.5
D.pb mean wheal (mm[SD]) 5.4  1.1 4.3  0.7 >0.5
FEV (%) 92.8  8.0 103.0  14.8 >0.5
PEF (%) 76.5  5.2 88.1  12.7 >0.5
Methacholine PC20: (mean) mg/mL 2.0  0.8 2.7  0.4 >0.5
a Dermatophagoides farinae.
b Dermatophagoides pteronyssinus.
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bronchial hyperreactivity
There was no significant difference at baseline between the
groups for threshold concentration of allergen-specific
nasal provocation. There was a significant increase of
threshold dose and subsequent nasal insensitivity within
the active group when compared to baseline (p Z 0.04) at
the end of treatment. On the other hand, within the pla-
cebo group and between groups, there were no statisticalTable 2 Clinical and laboratory parameters within and betwee
Symptoms & medications Active
0 Month 12 M
Sneezing 1.0  0.9 1.1 
Nasal blockage 0.8  1.1 0.6 
Nasal itching 0.8  1.0 0.9 
Rhinorrhea 1.0  1.0 0.8 
Total nasal symptom score 3.6  3.8 3.4 
Watery eyes 0.15  0.2 0.1 
Red eyes 0.3  0.4 0.3 
Itchy/Gritty eyes 0.2  0.4 0.3 
Total ocular symptom scores 3.6  3.8 0.7 
Total medication score 0.5  0.5 0.2 
Skin prick test
D.fa mean wheal (mm[SD]) 6.4  2.5 3.8 
D.pb mean wheal (mm[SD]) 5.4  1.1 3.6 
Nasal and lung function test
Specific nasal challenge (%) 100% 14%c
FEV1 (%) 92.8  8.0 100.
PEF (%) 76.5  5.2 98.8
Methacholine PC20 positivity (%) 66% 50%
a Dermatophagoides farinae.
b Dermatophagoides pteronyssinus.
c Statistical significance for intragroup differences between 0 and 1
d Comparison between groups at 12th month (ManneWhitney U ).
e Comparison between groups at 12 th month (chi-square).significance reached at the end of one year (p > 0.05 for
both) (Table 2).
Bronchial hyperreactivity to methacholine was detected
in 31% of the patients enrolled. Bronchial hypereactivity
was present in 66% of the patients in the SLIT group at
baseline and 50% at the end of one year. On the other hand,
although 20% of patients had BHR at baseline, this
increased to 75% of patients in the placebo group.
Although, methacholine test positivity of the two groups
was not significantly different at baseline (p > 0.05), it wasn the groups.
pd Placebo
onth 0 Month 12 Month
0.7 >0.05 0.7  0.5 0.9  0.7
0.8 >0.05 0.5  0.3 0.8  0.8
0.7 >0.05 0.5  0.8 0.8  0.8
0.7 >0.05 0.2  0.2 0.8  0.8
2.7 >0.05 2  1.6 3.3  3
0.3 >0.05 0.07  0.07 0.02  0.04
0.5 >0.05 0.1  0.2 0.02  0.04
0.5 >0.05 0.1  0.1 0.01  0.01
1.3c >0.05 2.0  1.5 0.04  0.1c
0.4 >0.05 0.3  0.3 0.8  1.4
3.0 >0.05 3.9  1.8 7.2  2.7
2.3 0.018 4.3  0.7 8.0  3.0
>0.05e 100% 22%
5  5.7 >0.05 103  14.8 110  9.1
 14.2 >0.05 88.1  12.7 107.6  6.1
>0.05e 20% 75%
2 months : p < 0.05 Wilcoxon.
Total Rhinitis symptoms Total Conjunctivitis symptoms
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Figure 2 Comparison of rhinoconjunctivitis symptoms between baseline and 1 year after treatment: (A) total rhinitis symptom
scores (TRSS); (B) total conjunctivitis symptom scores (TCSS); SLIT, half open circles and Placebo, complete circle. *p < 0.05; ns,
non-significance.
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compared to baseline (Table 2).
Safety
There were no local or systemic adverse events reported in
placebo group. One patient in the active group reported
having persistence nausea and vomiting immediately after
commencement of maintenance (300 IR) dose duringA DP Skin prick wheal
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Figure 3 Comparison of skin reactivity wheal against HDM (mm
pharmagoides pteronissinuss (DP); (B) Dermatopharmagoides farinupdosing, which necessitated the discontinuation of treat-
ment within the first month of treatment (Fig. 1).
Discussion
This study evaluated the efficacy of SLIT in children with AR
sensitized to HDM. This randomized, double-blind study
compared HDM-SLIT treatment with an active allergen
extract and placebo. The results of our study demonstratedB DF Skin prick wheal
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) between baseline and 1 year after treatment. (A) Dermato-
ae (DF); SLIT, half open circles and Placebo, complete circle.
1328 M. Aydogan et al.that 0ne year treatment with HDM-SLIT was not better than
placebo in reducing rhinitis symptoms in HDM-allergic
children. However, SLIT was capable of decreasing the
skin reactivity to the sensitized allergen and reduced the
specific allergen nasal reactivity and ameliorated devel-
opment of BHR in children with AR sensitized to HDM.
Present study was designed solely to evaluate the effect
of SLIT on rhinitis patients. The sample size anticipated to
be studied was not satisfactory in that, only 22 patients
with eligible criteria as being exclusively perennial AR who
were mono-sensitized to HDM and aged less than 10 years
were available for the study. During a two months run-in
period, 2 patients withdrew due to development of asth-
matic symptoms. The inclusion criteria used in this study
was more specific for a group with high risk for develop-
ment of asthma which made it difficult in selecting and
recruiting patients with isolated HDM-rhinitis. It has been
also noted that the highest incidence of asthma occurred at
earlier ages compared to AR [15]. Hence, most of those who
are sensitized to perennial allergens such as HDM have
increased risk of developing asthma at early age of life [16].
A substantial progress has been made in obtaining clin-
ical evidence of allergen immunotherapy in children with
respiratory allergy, with some unmet needs identified
recently [17]. There are few published DBPC trials that
evaluated efficacy of HDM-SLIT on AR in children with
contradictory results [18e22]. Recently, Yuksel et al
compared head to head the efficacy of SCIT and SLIT in
HDM-allergic children and reported that SCIT significantly
reduced rhinitis symptoms compared to SLIT and placebo,
with no difference between SLIT and placebo [23]. It might
be argued that most of the studies reported previosly
included patients with multiallergen and other comorbid-
ities such as asthma, hence effectivity of SLIT to treat
perennial AR could be obscured. The present study is robust
in that, we included HDM monosensitised perennial AR and/
conjunctivitis children without asthma symptoms and fol-
lowed for one year with daily evaluation of their symptoms.
Although SLIT was found to be globally effective from
recent systemic reviews and meta-analysis, inconclusive
results were reported when sub-analyses were conducted
by selecting HDM-trials [9,24e26]. Recently, Compalati
et al analysed HDM-SLIT trials in both children and adults,
demonstrating weak efficacy in rhinitis compared to asthma
symptoms [9]. Furthermore, treatment of AR with SLIT in
pediatric patients, involving 10 trials were analysed
showing that SLIT with pollen extracts was effective
compared to those treated with HDM-SLIT [24]. The possi-
bility of underreporting of negative results of HDM-specific
immunotherapy studies should also be considered [27]. Our
study which used high dose SLIT, has demonstrated that
HDM-SLIT can reduce skin reactivity and non-specific BHR
and increase allergen-specific nasal provocation threshold
with no effect on rhinitis or conjunctivitis symptoms which
is in line with previously reported evidence [28]. Further-
more, no significant changes between active and placebo
on total or individual conjunctivitis symptoms was found in
the current study, which is in accordance with a recent
meta-analysis of the effect of SLIT on perennial conjunc-
tivitis [29].
On the contrary, efficacy of HDM-SLIT has been demon-
strated in a number of studies to be effective in reducingasthmatic symptoms [9,17]. Further to this, a long term
treatment of low dose HDM-SLIT as an adjunct to pharma-
cotherapy resulted in reduction of both the duration and
dose of inhaled corticosteroids (ICSs) and successful
discontinuation along with improvement in lung functions in
HDM-allergic children with asthma [30]. Our study has also
demonstrated that 31% of allergic rhinitis children had BHR
which was comparable with the magnitude found in other
studies [31]. There is evidence showing that HDM-SLIT may
be an effective treatment in reducing BHR for patients with
rhinitis. Marogna et al. demonstrated that SLIT therapy
given for 2e3 years might be sufficient to maintain the
benefits of reduction in BHR even after 5e6 years post
treatment [32]. This effect on BHR was also observed by
Pichler et al in which SCIT with mite exerted continuous
improvement in BHR throughout the 3 years of treatment
[33]. Therefore, the results of one year treatment in our
study are in accordance with the previous findings. We
could not evaluate the effect of SLIT on asthma prevention
due to the low number of subjects and treatment duration.
A decrease in early skin reactivity to HDM extract after
SLIT has already been documented before [17,34]. The
immunologic mechanism underlying this effect was pro-
posed to be both downregulation of pro-inflammatory cells
and upregulation of blocking IgG antibodies as well as IL-10
production which occurs within days following immuno-
therapy [35]. This was further demonstrated that AIT re-
sults in early induction of peripheral IL-10 responses, serum
concentration of IgG4 and IgA antibodies as early as 3
months which in turn results in suppression of cutaneous
allergen responses [36]. In the present study, we found
significant reduction of HDM-specific skin reactivity in
active treatment group compared to placebo with no cor-
relation to clinical efficacy.
In conclusion, results of this study implicates that, HDM-
SLIT has a modulating effect on allergen-specific nasal,
skin reactivity and bronchial responsiveness, with no su-
periority clinical effect on rhinitis symptoms compared to
placebo in HDM-sensitized rhinitics children after one year
of treatment.
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